Trader consensus on a 96.5% implied probability of “No” for a hantavirus vaccine in 2026 reflects the early developmental stage of all candidates. Multiple mRNA platforms, including those from Moderna with Korea University and UTMB’s single-dose Andes virus constructs, have shown strong preclinical protection in rodent models as of mid-2026, yet none have advanced beyond Phase 1 or entered pivotal efficacy trials. No FDA- or EMA-approved product exists for relevant strains, and historical DNA or inactivated vaccine efforts remain limited to safety and immunogenicity data without large-scale field testing. The disease’s low incidence further complicates rapid Phase 3 enrollment absent major new funding or an emergency-use pathway. A late-2026 breakthrough would require unprecedented acceleration beyond current timelines.